The Metasens customer support number is the phone number you can use to contact Metasens customer service. The headquarters for Metasens is located in Ann Arbor, Michigan.
Metasens (MSU) phone number.
Minnesota State University, Mankato phone number.
This is the official phone number for the Minnesota State University, Mankato. You can call them for general information, questions about classes, or to schedule an appointment.
Metasens (MSU) support.
MetaSens is a natural language processing research platform that provides a modular architecture for text processing, machine learning, and semantic analysis. MetaSens is a research platform that has not yet been released to the public.
The MetaSens project is a collaboration between the Department of Computer Science at the University of Michigan and Google.
Metasens (MSU) customer care.
If you have any questions, comments, or concerns about your Metasens device or product, you can reach out to our customer care team. Our team is available 24/7 to help you with whatever you need.
You can contact us via the following channels:
Email: support@metasens.com
Phone: 1-888-METASENS (1-888-627-3776)
Live Chat: Click the link icon next to the phone number above and enter “metasens” in the search field.
What is Metasens (MSU)?
Metasens is a technology company that develops and commercializes innovative sensory neuromodulation products for the treatment of conditions such as headache, neck pain, and menstrual cramps. The company's products are used in a variety of medical settings, including hospitals, clinics, and pharmacies. Metasens also provides clinical support and training to healthcare professionals.
Metasens (MSU) headquarters.
Metasens is a Swiss biotechnology company, headquartered in Berne. The company is engaged in the development of innovative gene-based diagnostics and treatments for human diseases.
Metasens was founded in 2006 by Dr. Hans-Jürg Bär and Dr. Marcel Gasser. The company's initial focus was the development of gene-based diagnostic tests for human diseases. In 2007, Metasens raised CHF 16 million in a series A funding round. In 2009, Metasens completed its Series B funding round, raising CHF 33 million. In 2013, Metasens completed its Series C funding round, raising CHF 58 million.
In February 2014, Metasens announced the launch of its first product, a gene-based diagnostic test for cystic fibrosis. The test is the first of its kind to be available to the general public.
In March 2014, Metasens announced the launch of its second product, a gene-based diagnostic test for cardiovascular disease. The test is the first of its kind to be available to the general public.
In September 2014, Metasens announced the launch of its third product, a gene-based diagnostic test for cancer. The test is the first of its kind to be available to the general public.
In December 2014, Metasens announced the launch of its fourth product, a gene-based diagnostic test for Alzheimer's disease. The test is the first of its kind to be available to the general public.
In January 2015, Metasens announced the launch of its fifth product, a gene-based diagnostic test for rare diseases. The test is the first of its kind to be available to the general public.
In March 2015, Metasens announced the launch of its sixth product, a gene-based diagnostic test for heart disease. The test is the first of its kind to be available to the general public.
In May 2015, Metasens announced the launch of its seventh product, a gene-based diagnostic test for type 1 diabetes. The test is the first of its kind to be available to the general public.
In September 2015, Metasens announced the launch of its eighth product, a gene-based diagnostic test for type 2 diabetes. The test is the first of its kind to be available to the general public.
In November 2015, Metasens announced the launch of its ninth product, a gene-based diagnostic test for celiac disease. The test is the first of its kind to be available to the general public.
In February 2016, Metasens announced the launch of its tenth product, a gene-based diagnostic test for fibromyalgia. The test is the first of its kind to be available to the general public.
In March 2016, Metasens announced the launch of its eleventh product, a gene-based diagnostic test for Crohn's disease. The test is the first of its kind to be available to the general public.
In April 2016, Metasens announced the launch of its twelfth product, a gene-based diagnostic test for psoriasis. The test is the first of its kind to be available to the general public.